Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
New England Journal of Medicine · 14.08.2025 · 393 (7) · 648-659
DOI: 10.1056/nejmoa2502082 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 14.08.2025. Verfasst von Melanie J Davies und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, University of Leicester, Leicester, United Kingdom. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Overweight, Weight Loss. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Novo Nordisk A/S.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.
- NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom.
- Endocrine and Metabolic Research, LMC Healthcare, Brampton, ON, Canada.
- Novo Nordisk, Søborg, Denmark.
- Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham.
- Diabetes Complications Research Centre, University College Dublin School of Medicine, Dublin.
ORCID-Profile: Ildiko Lingvay, Julio Rosenstock
Förderung
- Novo Nordisk A/S
Zitieren
APA
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., Pedersen, S. D., & REDEFINE 2 Study Group (2025). Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 393(7), 648-659. https://doi.org/10.1056/nejmoa2502082
Vancouver
Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393(7):648-659. doi:10.1056/nejmoa2502082
BibTeX
@article{Davies2025,
author = {Davies, Melanie J and Bajaj, Harpreet S and Broholm, Christa and Eliasen, Astrid and Garvey, W Timothy and le Roux, Carel W and Lingvay, Ildiko and Lyndgaard, Christian Bøge and Rosenstock, Julio and Pedersen, Sue D and REDEFINE 2 Study Group, REDEFINE 2 Study Group},
title = {Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {7},
pages = {648--659},
doi = {10.1056/nejmoa2502082}
}
EUVIMED